A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT06657144
Phase
PHASE1
Sponsor
Coherus Oncology, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • CHS-114
  • Toripalimab
  • 5 Fluorouracil
  • Cisplatin
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Duarte, California, United States|34.13945,-117.97729
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Atlanta, Georgia, United States|33.749,-84.38798
  • New Orleans, Louisiana, United States|29.95465,-90.07507

Key Eligibility Criteria

  • At least 1 measurable lesion based on RECIST v1.1 as determined by the Investigator.
  • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI)-Common Terminology C…
  • Cohort A (2L Gastric, Gastro-esophageal-junction \[GEJ\], Esophageal Adenocarcinoma \[EAC\]) Specific Inclusion Criteria:
  • Histologically or cytologically documented unresectable, locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma that is human ep…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →